Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal indomethacin versus oral melatonin for prevention of post-ERCP pancreatitis
IRCT20121021011192N6Phase 4Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of indomethacin and melatonin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Occurrence of pancreatitis. Started Aug 2017; status: completed.
02
Drugs
indomethacinmelatonin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on IRCT20121021011192N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20121021011192N6.